Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Moderately aligned with label excerpts for IV administration, dose-related receptor effects, shock-syndrome indication framing, monitoring requirements, extravasation consequences, and several arrhythmia-related safety/interactions concepts. Several claims are not supported by the provided label sections (notably emergency hypotension nonresponse; Parkinson’s disease use statement; generic/patent status; and multiple specific adverse reactions). Additionally, important label areas (full dosing, boxed warnings, complete adverse reactions/precautions) are not present in the provided excerpts, limiting audit completeness.
Category Scores
Accurate Statements
Dopamine hydrochloride is administered intravenously.
DESCRIPTION: 'intended for intravenous use only.'
At low doses, dopamine hydrochloride primarily stimulates dopamine receptors in the kidneys, which can lead to increased blood flow and urine output.
CLINICAL PHARMACOLOGY: low rates (0.5-2 mcg/kg/min) cause vasodilation presumed due to dopamine receptors in renal/mesenteric/coronary/intracerebral beds; accompanied by increased renal blood flow and urine flow.
At moderate doses, dopamine hydrochloride stimulates beta-adrenergic receptors, which increases heart rate and contractility and thereby improves the heart's pumping ability and blood pressure.
CLINICAL PHARMACOLOGY: intermediate rates (2-10 mcg/kg/min) stimulate beta1-adrenoceptors; improved myocardial contractility; increased SA rate; usually increases systolic and pulse pressure.
At higher doses, dopamine hydrochloride stimulates alpha-adrenergic receptors, causing blood vessels to constrict and further raising blood pressure.
CLINICAL PHARMACOLOGY: higher rates (10-20 mcg/kg/min) have alpha-adrenoceptor effects with vasoconstrictor effects and rise in blood pressure.
Dopamine hydrochloride use requires careful monitoring because it significantly impacts the cardiovascular system.
PRECAUTIONS (Careful Monitoring Required): close monitoring of urine flow, cardiac output and blood pressure during infusion is necessary.
Dopamine hydrochloride can cause tissue damage if it leaks out of the vein (extravasation).
PRECAUTIONS (Extravasation): 'Extravasation may cause necrosis and sloughing of surrounding tissue.'
Unsupported Statements
Dopamine hydrochloride is a synthetic form of the naturally occurring neurotransmitter dopamine.
Not supported by the provided label excerpts.
Dopamine hydrochloride is primarily used as a medication to increase blood pressure and improve cardiac output in certain medical conditions.
Partially supported for hemodynamic correction/shock and inotropic/blood pressure effects; however the provided excerpts do not substantiate the word 'primarily' or specifically 'improve cardiac output' as the primary use wording.
Dopamine hydrochloride is used in emergency settings to treat hypotension that does not respond to other treatments.
No emergency nonresponse-to-other-treatments wording or conditionality is present in the provided label excerpts.
Dopamine hydrochloride is indicated for cardiogenic shock.
The provided indication excerpt references shock syndrome due to myocardial infarctions, but 'cardiogenic shock' is not explicitly stated in the supplied excerpt.
Dopamine hydrochloride is indicated for septic shock.
The provided indication excerpt references endotoxic septicemia; 'septic shock' is not explicitly stated in the supplied excerpt.
Dopamine hydrochloride is indicated for other forms of circulatory collapse where maintaining adequate blood pressure is critical for organ perfusion.
The provided indication excerpt supports shock due to multiple causes and mentions hemodynamic parameters (urine flow, myocardial function, blood pressure) but does not explicitly state 'organ perfusion.'
Dopamine hydrochloride as a medication is not used to treat Parkinson's disease directly due to its systemic effects and inability to cross the blood-brain barrier effectively.
The label excerpt says dopamine does not cross the blood-brain barrier to a significant extent, but there is no Parkinson’s disease indication and no explicit statement about not using dopamine hydrochloride for Parkinson’s.
Potential side effects of dopamine hydrochloride include chest pain.
No 'chest pain' adverse reaction is provided in the provided label excerpts.
Potential side effects of dopamine hydrochloride include headache.
No 'headache' adverse reaction is provided in the provided label excerpts.
Potential side effects of dopamine hydrochloride include anxiety.
No 'anxiety' adverse reaction is provided in the provided label excerpts.
Generic versions of dopamine hydrochloride have been available for many years.
Not supported by the provided label excerpts.
Dopamine hydrochloride is a well-established generic medication.
Not supported by the provided label excerpts.
Dopamine hydrochloride does not have active patents protecting its original development and marketing exclusivity.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
At low doses, dopamine hydrochloride primarily stimulates dopamine receptors in the kidneys, which can lead to increased blood flow and urine output.
Label Reference
CLINICAL PHARMACOLOGY: low-dose effects are dose-related and vasodilation is 'presumed' due to specific agonist action on dopamine receptors in multiple vascular beds (renal, mesenteric, coronary, intracerebral).
Important Omissions
The response did not provide labeled dosing/infusion rate ranges, titration approach, and specific dosage-and-administration instructions. The provided label excerpt includes clinical pharmacology rate ranges and general overdosage guidance, but no comprehensive dosing section was supplied for audit.
Importance:
Moderate
The response did not address labeled contraindications beyond extraneous arrhythmia-related statements (e.g., pheochromocytoma; uncorrected tachyarrhythmias/ventricular fibrillation; dextrose-containing solution allergy considerations).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims introduce adverse reactions (chest pain, headache, anxiety) and indication framing (septic shock/cardiogenic shock as explicit diagnoses; emergency hypotension nonresponse) that are not supported by the provided label excerpts. These could mislead users about labeled safety profile and labeled use conditions. However, key supported safety elements present in the label excerpts (monitoring indices and extravasation consequences; arrhythmia-related caution through contraindications/interactions) reduce overall risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple statements are not supported by the provided label excerpts, including emergency nonresponse language, explicit septic/cardiogenic shock labeling, Parkinson’s disease use statement, and specific adverse reactions (chest pain, headache, anxiety).
Suggested Improvement
Restrict claims to elements explicitly supported by the provided label text (e.g., IV-only, shock syndrome indication wording as provided, dose-rate receptor effects, labeled monitoring indices, contraindication/interactions/arrhythmia cautions, and extravasation necrosis/sloughing). Remove or qualify unsupported adverse reaction and labeling-status/patent/generic-history claims, and provide the missing label sections (boxed warnings, full dosage & administration, complete adverse reactions, and full contraindications) before concluding broader safety/usage assertions.